Routes of
administration Oral Legal status Investigational Biological half-life ~20 hours | ATC code none Bioavailability Unaffected by food Molar mass 426.41 g/mol | |
 | ||
Metabolism | ||
Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2).
As of 2016, it is in Phase III clinical trials for the treatment of asthma.
References
Fevipiprant Wikipedia(Text) CC BY-SA